Iron accumulates in Huntington's disease neurons: protection by deferoxamine.

Huntington's disease (HD) is a progressive neurodegenerative disorder caused by a polyglutamine-encoding CAG expansion in the huntingtin gene. Iron accumulates in the brains of HD patients and mouse disease models. However, the cellular and subcellular sites of iron accumulation, as well as sig...

Full description

Bibliographic Details
Published in:	PLoS ONE
Main Authors:	Jianfang Chen, Eileen Marks, Barry Lai, Zhaojie Zhang, James A Duce, Linh Q Lam, Irene Volitakis, Ashley I Bush, Steven Hersch, Jonathan H Fox
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Online Access:	http://europepmc.org/articles/PMC3795666?pdf=render

Similar Items

Correction: Iron Accumulates in Huntington’s Disease Neurons: Protection by Deferoxamine.
by: Jianfang Chen, et al.
Published: (2013-01-01)

Correction: Iron Accumulates in Huntington’s Disease Neurons: Protection by Deferoxamine
Published: (2013-01-01)

Altered selenium status in Huntington's disease: Neuroprotection by selenite in the N171-82Q mouse model
by: Zhen Lu, et al.
Published: (2014-11-01)

Deferoxamine suppresses neuronal damage in T1DM rats by reducing cerebral iron content
by: CI Yunzhe, et al.
Published: (2025-10-01)

High ferritin is associated with liver and bone marrow iron accumulation: Effects of 1-year deferoxamine treatment in hemodialysis-associated iron overload.
by: Lucas L A Nunes, et al.
Published: (2024-01-01)

Development of Deferoxamine‐Functionalized Cyclodextrin Polymer for Targeted Iron Chelation
by: Roberta Panebianco, et al.
Published: (2025-10-01)

Combined Deferoxamine - Deferasirox in Treatment of Thalassemia Major with Iron Overload
by: Abdul Kareem A. Mahmood, et al.
Published: (2014-04-01)

The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity
by: Masanari Umemura, et al.
Published: (2017-08-01)

Screen-Printed Gold Electrode Functionalized with Deferoxamine for Iron(III) Detection
by: Giancarla Alberti, et al.
Published: (2022-06-01)

Re: "Protective Role of Silymarin and Deferoxamine against Iron Dextran-Induced Renal Iron Deposition in Male Rats," and "Co-Administration of Silymarin and Deferoxamine against Kidney, Liver and Heart Iron Deposition in Male Iron Overload Rat Model"
by: Safoora Mazaheri, et al.
Published: (2014-01-01)

Deferoxamine ameliorates adipocyte dysfunction by modulating iron metabolism in ob/ob mice
by: Hong-Fa Yan, et al.
Published: (2018-04-01)

Protective role of silymarin and deferoxamine against iron dextran-induced renal iron deposition in male rats
by: Mehdi Nematbakhsh, et al.
Published: (2013-01-01)

β-Amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin.
by: Bruce X Wong, et al.
Published: (2014-01-01)

Ameliorating Iron Overload in Intestinal Tissue of Adult Male Rats: Quercetin vs Deferoxamine
by: Arwa A. El-Sheikh, et al.
Published: (2018-01-01)

Histopathological Changes of Heart, Liver, and Duodenum in Iron Overload: ‎Comparing the Role of Quercetin with Deferoxamine
by: Muntasser A Awad, et al.
Published: (2023-12-01)

Iron chelation by deferoxamine prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction.
by: Yasumasa Ikeda, et al.
Published: (2014-01-01)

Iron Chelator Deferoxamine Alleviates Progression of Diabetic Nephropathy by Relieving Inflammation and Fibrosis in Rats
by: Yunfei Feng, et al.
Published: (2023-08-01)

Comparative Efficacy of Deferiprone, Deferoxamine and Combination of Deferiprone and Deferoxamine on Serum Ferritin Value in Beta-Thalassemia Patients
by: Nargesbeygom Mirbehbahani, et al.
Published: (2015-01-01)

Co-administration of silymarin and deferoxamine against kidney, liver and heart iron deposition in male iron overload rat model
by: Mitra Navidi-Shishaone, et al.
Published: (2014-01-01)

Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload
by: Gotsis Efstathios D, et al.
Published: (2011-07-01)

Study protocol of IMAGINE-HD: Imaging iron accumulation and neuroinflammation with 7T-MRI + CSF in Huntington’s disease
by: Nadine Anniek van de Zande, et al.
Published: (2023-01-01)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
by: Taher AT, et al.
Published: (2016-12-01)

A Novel Star Like Eight-Arm Polyethylene Glycol-Deferoxamine Conjugate for Iron Overload Therapy
by: Bohong Yu, et al.
Published: (2020-04-01)

Mechanisms of Intranasal Deferoxamine in Neurodegenerative and Neurovascular Disease
by: Jacob Kosyakovsky, et al.
Published: (2021-01-01)

Abstract: Deferoxamine Increases Breast Cancer Radiosensitivity
by: Kavitha Ranganathan, MD, et al.
Published: (2018-09-01)

The ubiquitin-proteasome reporter GFPu does not accumulate in neurons of the R6/2 transgenic mouse model of Huntington's disease.
by: John S Bett, et al.
Published: (2009-01-01)

Low-dose intranasal deferoxamine modulates memory, neuroinflammation, and the neuronal transcriptome in the streptozotocin rodent model of Alzheimer’s disease
by: Jared M. Fine, et al.
Published: (2025-01-01)

Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine
by: Mohamed Abdel Malik Hassan, et al.
Published: (2016-05-01)

Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia
by: Hayder M Al-Kuraishy, et al.
Published: (2017-01-01)

Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice
by: Fran Norflus, et al.
Published: (2004-11-01)

Deferoxamine Promotes MDA-MB-231 Cell Migration and Invasion through Increased ROS-Dependent HIF-1α Accumulation
by: Yiping Liu, et al.
Published: (2014-04-01)

Differential response of neurons to autophagy modulation in Huntington’s disease
by: Ankit Sharma, et al.
Published: (2025-12-01)

Metabolic dysregulation in Huntington's disease: Neuronal and glial perspectives
by: Ching-Pang Chang, et al.
Published: (2024-10-01)

Abstract 86: Altered Iron-Mediator Expression Identifies Chemotherapeutic Effects of Deferoxamine on Head and Neck Squamous Cell Carcinoma
by: Alexis Donneys, MD, MS, et al.
Published: (2019-04-01)

Deferoxamine therapy for intracerebral hemorrhage: A systematic review.
by: Liling Zeng, et al.
Published: (2018-01-01)

Deferoxamine-Based Materials and Sensors for Fe(III) Detection
by: Giancarla Alberti, et al.
Published: (2022-11-01)

Application of Deferoxamine in Tissue Regeneration Attributed to Promoted Angiogenesis
by: Haijun Shen, et al.
Published: (2024-04-01)

Development of green chemistry and sensitive method for preconcentration and determination of iron ions with modified multiwall carbon nanotubes using deferoxamine mesylate
by: Mitra Ardakani, et al.
Published: (2024-08-01)

An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cells
by: Koichi Fujisawa, et al.
Published: (2022-05-01)

Abnormal degradation of the neuronal stress-protective transcription factor HSF1 in Huntington’s disease
by: Rocio Gomez-Pastor, et al.
Published: (2017-02-01)